Dust mite-derived Enterobacterial fimbriae H protein enforces the allergen specific immunotherapy in asthma mice

Main Article Content

X. Yang
H. Wang
D. Zhao
J. Wang
X. Liu
X. Yuan
M. Zhang
G. Li
P. Ran
P. Yang
Z. Liu

Keywords

Allergen specific immunotherapy, House dust mite, Enterobacterial fimbriae H protein, Tregs, Adjuvant effect

Abstract

Background: The mite alimentary canal contains plenty of microbiota. It is accepted that some of the microbial products function as adjuvants to speed up immune responses.


Objectives: We identified five bacterial proteins from dust mite, and Enterobacterial fimbriae H (FimH) was one of them. This study aims to test a hypothesis that the FimH protein enforces immunotherapy in asthmatic mice.


Methods: Asthmatic mice were treated by allergen specific immunotherapy (ASIT) with rDer f1/f2 or rDer f1/f2 plus FimH. Changes in inflammatory cell infiltration, airway hyperactivity, frequency of Tregs, splenic CD4+ IFN-y+ cells, and serum levels of TGF-, IL-10, IL-13 and IL-17A of asthmatic mice were checked.


Results: ASIT with rDer f1/f2 plus FimH reduced inflammatory cell infiltration, airway hyperreactivity (AHR), and levels of IgE and IgG1 compared to ASIT with rDer f1/f2 alone, but the levels of IgG2a increased. Asthmatic mice that underwent ASIT with rDer f1/f2 plus FimH showed increased frequency of Tregs, splenic CD4+ IFN-y+ cells, serum levels of TGF- and IL10; and deceased splenic CD4+ IL-4+ cells, and serum levels of IL-13 and IL-17A. In vitro study showed FimH triggered IL-10 expression in a concentration-dependent manner and facilitated the differentiation of Tregs.


Conclusion: Used as an adjuvant, FimH enforces the effect of ASIT in asthmatic mice via augmenting Tregs.

Abstract 139 | PDF Downloads 181

References

1. Zhang C, Li J, Lai X, Zheng Y, Gjesing B, Spangfort MD, et al. House dust mite and storage mite IgE reactivity in allergic patients from Guangzhou, China. Asian Pac J Allergy Immunol. 2012;30:294-300.

2. Schulze J, Voss S, Zissler U, Rose MA, Zielen S, Schubert R. Airway responses and inflammation in subjects with asthma after four days of repeated high-single-dose allergen challenge. Respir Res. 2012;13:78.

3. Gjomarkaj M, Pace E, Canonica GW, Bonini S, Ricci G, Burney P, et al. [GA(2)LEN (Global Allergy and Asthma European Network): European network of excellence for asthma and allergic diseases]. Minerva Med. 2009;100:525-34.

4. Zhang F, Hang J, Zheng B, Su L, Christiani DC. The changing epidemiology of asthma in Shanghai, China. J Asthma. 2015;52:465-70.

5. Chen ZH, Wang PL, Shen HH. Asthma research in China: a fiveyear review. Respirology. 2013;18 Suppl 3:10-9.

6. Bai J, Zhao J, Shen KL, Xiang L, Chen AH, Huang S, et al. Current trends of the prevalence of childhood asthma in three Chinese cities: a multicenter epidemiological survey. Biomed Environ Sci. 2010;23:453-7.

7. Zubeldia JM, Ferrer M, Dávila I, Justicia JL. Adjuvants in allergen-specific immunotherapy: modulating and enhancing the immune response. J Investig Allergol Clin Immunol. 2019;29:103-11.

8. Nelson HS. Allergen immunotherapy now and in the future. Allergy Asthma Proc. 2016;37:268-72.

9. Eifan AO, Calderon MA, Durham SR. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther. 2013;13:1543-56.

10. Eifan AO, Akkoc T, Yildiz A, Keles S, Ozdemir C, Bahceciler NN, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy. 2010;40:922-32.

11. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102 4 Pt 1:558-62.

12. Johansen P, von Moos S, Mohanan D, Kundig TM, Senti G. New routes for allergen immunotherapy. Hum Vaccin Immunother. 2012;8:1525-33.

13. Focke-Tejkl M, Valenta R. Safety of engineered allergen-specific immunotherapy vaccines. Curr Opin Allergy Clin Immunol. 2012;12:555-63.

14. Casale TB, Stokes JR. Future forms of immunotherapy. J Allergy Clin Immunol. 2011;127:8-15, 16-17.

15. Spertini F, Reymond C, Leimgruber A. Allergen-specific immunotherapy of allergy and asthma: current and future trends. Expert Rev Respir Med. 2009;3:37-51.

16. Chan TF, Ji KM, Yim AK, Liu XY, Zhou JW, Li RQ, et al. The draft genome, transcriptome, and microbiome of Dermatophagoides farinae reveal a broad spectrum of dust mite allergens. J Allergy Clin Immunol. 2015;135:539-48.

17. Mossman KL, Mian MF, Lauzon NM, Gyles CL, Lichty B, Mackenzie R, et al. Cutting edge: FimH adhesin of type 1 fimbriae is a novel TLR4 ligand. J Immunol. 2008;181:6702-6.

18. Ashkar AA, Mossman KL, Coombes BK, Gyles CL, Mackenzie R. FimH adhesin of type 1 fimbriae is a potent inducer of innate antimicrobial responses which requires TLR4 and type 1 interferon signalling. Plos Pathog. 2008;4:e1000233.

19. Francis JN, Durham SR. Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Curr Opin Allergy Clin Immunol. 2004;4:543-8.

20. Pfaar O, Cazan D, Klimek L, Larenas-Linnemann D, Calderon MA. Adjuvants for immunotherapy. Curr Opin Allergy Clin Immunol. 2012;12:648-57.

21. Tandon A, Pathak M, Harioudh MK, et al. A TLR4-derived non-cytotoxic, self-assembling peptide functions as a vaccine adjuvant in mice. J Biol Chem. 2018;293:19874-85.

22. Bussieres L, Bordas-Le FV, Bulder I, Chabre H, Nony E, Lautrette A, et al. Recombinant fusion proteins assembling Der p 1 and Der p 2 allergens from Dermatophagoides pteronyssinus. Int Arch Allergy Immunol. 2010;153:141-51.

23. Roque K, Shin KM, Jo JH, et al. Association between endotoxin levels in dust from indoor swine housing environments and the immune responses of pigs. J Vet Sci. 2018;19:331-8.

24. Palomares O, Martin-Fontecha M, Lauener R, Traidl-Hoffmann C, Cavkaytar O, Akdis M, et al. Regulatory T cells and immune regulation of allergic diseases: roles of IL-10 and TGF-beta. Genes Immun. 2014;15:511-20.

25. Iwasaki Y, Fujio K, Okamura T, Yamamoto K. Interleukin-27 in T cell immunity. Int J Mol Sci. 2015;16:2851-63.

26. de la Torre MV, Baeza ML, Nájera L, Zubeldia JM. Comparative study of adjuvants for allergen-specific immunotherapy in a murine model. Immunotherapy. 2018;10:1219-28.

27. Wheeler AW, Marshall JS, Ulrich JT. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int Arch Allergy Immunol. 2001;126:135-9.

28. Dhami S, Kakourou A, Asamoah F, et al. Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis. Allergy. 2017;72:1825-48.

29. Cappella A, Durham SR. Allergen immunotherapy for allergic respiratory diseases. Hum Vaccin Immunother. 2012;8:1499-512.

30. Lewkowicz P, Lewkowicz N, Sasiak A, Tchorzewski H. Lipopolysaccharide-activated CD4+CD25+T regulatory cells inhibit neutrophil function and promote their apoptosis and death. J Immunol. 2006;177:7155-63.

31. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J. 2015;8:17.

32. Fujita H, Meyer N, Akdis M, Akdis CA. Mechanisms of immune tolerance to allergens. Chem Immunol Allergy. 2012;96:30-8.

33. Palomares O, Yaman G, Azkur AK, Akkoc T, Akdis M, Akdis CA. Role of Treg in immune regulation of allergic diseases. Eur J Immunol. 2010;40:1232-40.

34. Bedoya SK, Lam B, Lau K, Larkin JR. Th17 cells in immunity and autoimmunity. Clin Dev Immunol. 2013;2013:986789.

35. Zhang Y, Zhang L, Wu J, Di C, Xia Z. Heme oxygenase-1 exerts a protective role in ovalbumin-induced neutrophilic airway inflammation by inhibiting Th17 cell-mediated immune response. J Biol Chem. 2013;288:34612-26.

36. Morishima Y, Ano S, Ishii Y, Ohtsuka S, Matsuyama M, Kawaguchi M, et al. Th17-associated cytokines as a therapeutic target for steroid insensitive asthma. Clin Dev Immunol. 2013;2013:609395.

37. Higgins SC, Lavelle EC, McCann C, Keogh B, McNeela E, Byrne P, et al. Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology. J Immunol. 2003;171:3119-27.

38. Mills KH. TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol. 2011;11:807-22.

39. Higgs R, Higgins SC, Ross PJ, Mills KH. Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol. 2012;5:485-500.